Protocol D5290C00003: A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healt

Project: Research project

Project Details

StatusActive
Effective start/end date9/1/168/31/50

Funding

  • MedImmune, Inc.
  • MedImmune, Inc.